Literature DB >> 22099102

Epidemic meningococcal meningitis, Cameroon.

D Massenet, D Vohod, H Hamadicko, D A Caugant.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 22099102      PMCID: PMC3310568          DOI: 10.3201/eid1711.110468

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: In 2010, the city of Ngaoundéré in Cameroon experienced its first reported epidemic of meningococcal meningitis. Ngaoundéré, with an estimated population of 180,000, is the main city in the Adamaoua region in northern Cameroon. The 2 northernmost regions of Cameroon, North and Far North, are considered to belong to the African meningitis belt () and are periodically affected by meningococcal meningitis outbreaks. However, the Adamaoua region had been spared because of its altitude, latitude, and low population density in comparison with the North and Far North regions. Fewer than 10 sporadic cases have been reported in the Adamaoua region every year. During February–April 2010, a total of 126 cases of meningitis (70 cases/100,000 inhabitants) were reported in the Adamaoua region. Of the 126 cases, 34 were confirmed by identification of Neisseria meningitidis serogroup A in cerebrospinal fluid (CSF) samples, 46 cases were apparent meningitis in which the patients had turbid CSF, and 46 were clinical cases diagnosed in an epidemic context. The male:female ratio of the patients was 2.7:1. The mean age of patients was 19 years, and median was 17 years. CSF specimens from 34 patients were sent to the Centre Pasteur du Cameroun in Garoua for testing. Laboratory procedures included assessing CSF turbidity, Gram staining, searching for soluble capsular antigens by using the Pastorex latex agglutination kit (Bio-Rad, Hercules, CA, USA), and testing by the dipstick rapid diagnostic test for N. meningitidis serogroups A, C, W135, and Y (provided by the Centre de Recherche Médicale et Sanitaire, Niamey, Niger). All 34 specimens were positive for serogroup A by agglutination, rapid test, or both. CSF specimens were cultured on blood agar and chocolate agar supplemented with PolyViteX (bioMérieux, Marcy-l’Etoile, France) and incubated at 37°C in an atmosphere of 5% CO2. Susceptibility to antimicrobial drugs was tested according to the recommendations of the Antibiogram Committee of the French Society for Microbiology (www.sfm.asso.fr). An isolate of N. meningitidis was sent to the World Health Organization Collaborating Centre for Reference and Research on Meningococci in Oslo, Norway, for molecular analyses, as described (www.neisseria.org). The result was that the isolate, a N. meningitidis serogroup A clone of sequence type 7, was susceptible to β-lactams and chloramphenicol but resistant to trimethoprim/sulfamethoxazole. This epidemic occurred in an area where the mean annual rainfall for the past 30 years was 1,460 mm (Agency for Aerial Navigation Safety in Africa and Madagascar, unpub. data). This value should exclude Ngaoundéré from the African meningitis belt, for which the southern limit of annual rainfall was classically considered to be the 1,100-mm isohyet (Figure).
Figure

Northern regions of Cameroon with mean annual rainfall. Maroua is at the 800 mm isohyet line, Garoua at 1,006 mm, and Ngaoundéré at 1,460 mm. Estimate for Maroua is by the Agency for Aerial Navigation Safety in Africa and Madagascar; recorded rainfall for Garoua and Ngaoundéré are by the Agency for Aerial Navigation Safety in Africa and Madagascar. Eq. Guinea, Equatorial Guinea.

Northern regions of Cameroon with mean annual rainfall. Maroua is at the 800 mm isohyet line, Garoua at 1,006 mm, and Ngaoundéré at 1,460 mm. Estimate for Maroua is by the Agency for Aerial Navigation Safety in Africa and Madagascar; recorded rainfall for Garoua and Ngaoundéré are by the Agency for Aerial Navigation Safety in Africa and Madagascar. Eq. Guinea, Equatorial Guinea. This epidemic at the border of the African meningitis belt raises the question of the belt limitation and its potential expansion southward. These topics should be addressed through active and standardized surveillance in countries such as Cameroon, which are not entirely included in the belt (,). This meningitis epidemic has 2 other noteworthy characteristics. First, 80 (63%) of 126 suspected cases had a lumbar puncture performed at the Ngaoundéré Regional Hospital or at the Norwegian hospital. With the help of the laboratory, an increasing number of cases of meningitis in Cameroon are confirmed cases (). Second, the etiologic agent was serogroup A meningococcus, a serogroup that had not been identified in north Cameroon since 2006 () but that had been isolated previously () and in south Cameroon ().
  7 in total

1.  [CEREBROSPINAL MENINGITIS IN AFRICA].

Authors:  L LAPEYSSONNIE
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

Review 2.  Risk mapping and early warning systems for the control of meningitis in Africa.

Authors:  Luis E Cuevas; Isabelle Jeanne; Anna Molesworth; Michael Bell; Emily C Savory; Stephen J Connor; Madeleine C Thomson
Journal:  Vaccine       Date:  2007-05-07       Impact factor: 3.641

3.  [Impact of the biological monitoring of cerebrospinal meningitis on the notification of cases in North Cameroon].

Authors:  D Massenet; J Inrombe
Journal:  Rev Epidemiol Sante Publique       Date:  2009-12       Impact factor: 1.019

4.  A predictable comeback: the second pandemic of infections caused by Neisseria meningitidis serogroup A subgroup III in Africa, 1995.

Authors:  J Y Riou; S Djibo; L Sangare; J P Lombart; P Fagot; J P Chippaux; M Guibourdenche
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

5.  Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa.

Authors:  Anna M Molesworth; Madeleine C Thomson; Stephen J Connor; Mark P Cresswell; Andrew P Morse; Paul Shears; C Anthony Hart; Luis E Cuevas
Journal:  Trans R Soc Trop Med Hyg       Date:  2002 May-Jun       Impact factor: 2.184

6.  Serogroup A Neisseria meningitidis outside meningitis belt in southwest Cameroon.

Authors:  Patrick Cunin; Marie-Christine Fonkoua; Basile Kollo; B Atembeh Bedifeh; Paul Bayanak; Paul M V Martin
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

7.  Serogroup W135 meningococcal meningitis, Northern Cameroon, 2007-2008.

Authors:  Denis Massenet; Jermias Inrombe; Dave Etienne Mevoula; Pierre Nicolas
Journal:  Emerg Infect Dis       Date:  2009-02       Impact factor: 6.883

  7 in total
  3 in total

1.  Epidemiologic pattern of meningococcal meningitis in northern Cameroon in 2007-2010: contribution of PCR-enhanced surveillance.

Authors:  Denis Massenet; Jacques Birguel; François Azowé; Clifford Ebong; Bouba Gake; Jean-Pierre Lombart; Pascal Boisier
Journal:  Pathog Glob Health       Date:  2013-01       Impact factor: 2.894

2.  Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].

Authors:  D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood
Journal:  Lancet       Date:  2013-09-12       Impact factor: 79.321

3.  Hospital-based Surveillance Provides Insights Into the Etiology of Pediatric Bacterial Meningitis in Yaoundé, Cameroon, in the Post-Vaccine Era.

Authors:  Angeline Boula; Madikay Senghore; Rose Ngoh; Flaubert Tassadjo; Marie-Christine Fonkoua; Ariane Nzouankeu; Mina Kenkela Njiki; Jeanne Musi; Sandrine Bebey; Madeline Ngo Baleba; Angeline Nkembe; Sidonie Médjina; Peter S Ndow; Archibald Worwui; Marie Kobela; Marceline Nimpa; Jason M Mwenda; Aboubacar N'diaye; Brenda A Kwambana-Adams; Martin Antonio
Journal:  Clin Infect Dis       Date:  2019-09-05       Impact factor: 9.079

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.